Vacc-4x(Bionor Pharma) success in Phase IIb trial for HIV/AIDS

Bionor Pharma announced a final review of phase IIb data for its vaccine, Vacc-4x, which confirms a statistically significant 64% reduction of viral load �set point� (average of the last two viral load measurements before the end of the study) in patients receiving Vacc-4x compared to those given placebo. The HIV viral load set point in patients given Vacc-4x was 60% lower than pre-ART (level before starting with standard medicine, ART). In the placebo group, no change compared to pre-ART was observed. The conclusive data will provide a basis for further HIV trials.